
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KNA-155
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Solid Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Solid Biosciences Inks Licensing Deal with Kinea Bio for Next-Gen Capsid AAV-SLB101 Use
Details : Kinea Bio will use Solid’s next-generation capsid, AAV-SLB101, for the development of KNA-155, an investigational dual AAV gene therapy.
Product Name : KNA-155
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 23, 2025
Lead Product(s) : KNA-155
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Solid Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KNA-155
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Jain Foundation
Deal Size : $1.1 million
Deal Type : Funding
Kinea Bio Secures $1.1M Investment to Advance Gene Therapy for Dysferlinopathy
Details : The funding will support the KNA-155, including dose-finding and GLP toxicology studies in dysferlin-deficient animal models.
Product Name : KNA-155
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 23, 2025
Lead Product(s) : KNA-155
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Jain Foundation
Deal Size : $1.1 million
Deal Type : Funding
